Optimization and Characterization of Brimonidine Tartrate Nanoparticles-loaded In Situ Gel for the Treatment of Glaucoma
- PMID: 33844617
- DOI: 10.1080/02713683.2021.1916037
Optimization and Characterization of Brimonidine Tartrate Nanoparticles-loaded In Situ Gel for the Treatment of Glaucoma
Abstract
Purposes: The present study aimed to develop brimonidine tartrate loaded poly(lactic-co-glycolic acid) acid vitamin E-tocopheryl polyethylene glycol 1000 succinate (BRT-PLGA-TPGS) nanoparticles in thermosensitivein situ gel to improve mucoadhensive properties and drug holding capacity for the better management of glaucoma.Methods: Nanoparticles was optimized by means of Box-Behnken Design (BBD). The formulations were prepared using various concentration of PLGA (0.1-0.4% w/v) and TPGS (0.3-0.5% w/v). The analytical data of fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC) and transmission electron microscopy (TEM) depicted the drug excipients compatibility and confirmed the nanoparticles. Nanoparticles incorporated gel was evaluated for transcorneal permeability, gelation time, gelling temperature, and rheological studies. In addition, in vitro, transcorneal permeation drug release studies and intraocular pressure (IOP) for optimized gel was also performed. Biocompatibility of formulations was investigated in rabbit model.Results: The drug loaded nanoparticles exhibited 115.72 ± 4.18 nm, 0.190 ± 0.02, -11.80 ± 2.24 mV and 74.85 ± 6.54% of mean size, polydispersity index (PDI), zeta potential and entrapment efficiency (% EE), respectively. As compared to marketed eye drop, the sustained and continuous release BRT release from Poloxamer-based in situ gel was 85.31 ± 3.51% till 24 h. The transcorneal steady-state flux (136.32 μg cm-2 h-1) of optimized in situ gel was approximately 3.5 times higher than marketed formulation (38.60 μg cm-2 h-1) flux at 4 h. The optimized formulation produces 3 fold greater influences on percentage reduction of IOP (34.46 ± 4.21%) than the marketed formulation (12.24 ± 2.90%) till 8 h.Conclusion: The incorporation of optimized BRT-PLGA-TPGS nanoparticles into a thermosensitivein situ gel matrix to improve precorneal residence time without causing eye irritation and also serve the sustained release of BRT through cornea for effective management of glaucoma.
Keywords: Box-Behnken design; Glaucoma; PLGA-TPGS nanoparticles; brimonidine tartrate; in situ gel; intraocular pressure.
Similar articles
-
Phase Transition Microemulsion of Brimonidine Tartrate for Glaucoma Therapy: Preparation, Characterization and Pharmacodynamic Study.Curr Eye Res. 2021 Dec;46(12):1844-1852. doi: 10.1080/02713683.2021.1942071. Epub 2021 Jun 28. Curr Eye Res. 2021. PMID: 34176380
-
Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study.Drug Deliv. 2019 Dec;26(1):509-521. doi: 10.1080/10717544.2019.1609622. Drug Deliv. 2019. PMID: 31090464 Free PMC article.
-
Novel topical ophthalmic formulations for management of glaucoma.Pharm Res. 2013 Nov;30(11):2818-31. doi: 10.1007/s11095-013-1109-1. Epub 2013 Jun 15. Pharm Res. 2013. PMID: 23771565
-
Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box-Behnken design.J Liposome Res. 2014 Sep;24(3):171-81. doi: 10.3109/08982104.2014.891231. Epub 2014 Mar 10. J Liposome Res. 2014. PMID: 24611687 Review.
-
Formulation optimization of etoposide loaded PLGA nanoparticles by double factorial design and their evaluation.Curr Drug Deliv. 2010 Jan;7(1):51-64. doi: 10.2174/156720110790396517. Curr Drug Deliv. 2010. PMID: 20044908 Review.
Cited by
-
Preparation and Characterization of Ion-Sensitive Brimonidine Tartrate In Situ Gel for Ocular Delivery.Pharmaceuticals (Basel). 2023 Jan 8;16(1):90. doi: 10.3390/ph16010090. Pharmaceuticals (Basel). 2023. PMID: 36678587 Free PMC article.
-
Nanoparticles for the treatment of glaucoma-associated neuroinflammation.Eye Vis (Lond). 2022 Jul 2;9(1):26. doi: 10.1186/s40662-022-00298-y. Eye Vis (Lond). 2022. PMID: 35778750 Free PMC article. Review.
-
Breaking Barriers in Eye Treatment: Polymeric Nano-Based Drug-Delivery System for Anterior Segment Diseases and Glaucoma.Polymers (Basel). 2023 Mar 9;15(6):1373. doi: 10.3390/polym15061373. Polymers (Basel). 2023. PMID: 36987154 Free PMC article. Review.
-
Novel Biomaterials in Glaucoma Treatment.Biomedicines. 2024 Apr 7;12(4):813. doi: 10.3390/biomedicines12040813. Biomedicines. 2024. PMID: 38672168 Free PMC article. Review.
-
Sustained release of brimonidine from polydimethylsiloxane-coating silicone rubber implant to reduce intraocular pressure in glaucoma.Regen Biomater. 2023 Apr 24;10:rbad041. doi: 10.1093/rb/rbad041. eCollection 2023. Regen Biomater. 2023. PMID: 37303848 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials